bioAffinity Technologies, Inc. (BIAF)
$2.8725
-0.19 (-6.13%)
Rating:
Recommendation:
-
| Symbol | BIAF |
|---|---|
| Price | $2.8725 |
| Beta | 0.000 |
| Volume Avg. | 1.33M |
| Market Cap | 24.042M |
| Shares () | - |
| 52 Week Range | 1.31-15.55 |
| 1y Target Est | - |
| DCF Unlevered | BIAF DCF -> | |
|---|---|---|
| DCF Levered | BIAF LDCF -> | |
| ROE | 95.62% | Strong Buy |
| ROA | -35.55% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 11.62% | Neutral |
| P/E | - | |
| P/B | 0.62 | Buy |
Latest BIAF news
About
Download (Excel)Ms. Maria Zannes J.D.
Healthcare
Diagnostics & Research
NASDAQ Capital Market
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.